[go: up one dir, main page]

WO2015023553A3 - Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules - Google Patents

Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules Download PDF

Info

Publication number
WO2015023553A3
WO2015023553A3 PCT/US2014/050465 US2014050465W WO2015023553A3 WO 2015023553 A3 WO2015023553 A3 WO 2015023553A3 US 2014050465 W US2014050465 W US 2014050465W WO 2015023553 A3 WO2015023553 A3 WO 2015023553A3
Authority
WO
WIPO (PCT)
Prior art keywords
administration
sulfur
modulation
amino acid
small molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/050465
Other languages
French (fr)
Other versions
WO2015023553A2 (en
Inventor
Frederick H. Hausheer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioNumerik Pharmaceuticals Inc
Original Assignee
BioNumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNumerik Pharmaceuticals Inc filed Critical BioNumerik Pharmaceuticals Inc
Publication of WO2015023553A2 publication Critical patent/WO2015023553A2/en
Publication of WO2015023553A3 publication Critical patent/WO2015023553A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of cellular metabolic anomalies or other undesirable physiological conditions, including cancer, where the normal cellular biochemical function and/or the expression levels of various proteins/enzymes (i.e., the target molecules) are abnormal and must be modified and/or modulated in order to treat these metabolic anomalies or other undesirable physiological conditions, including cancer. Administration of the most effective medicinal agent(s) to be administered in combination with the administration of the sulfur-containing, amino acid-specific small molecules is disclosed.
PCT/US2014/050465 2013-08-13 2014-08-10 Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur- containing, amino acid-specific small molecules Ceased WO2015023553A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361865360P 2013-08-13 2013-08-13
US61/865,360 2013-08-13

Publications (2)

Publication Number Publication Date
WO2015023553A2 WO2015023553A2 (en) 2015-02-19
WO2015023553A3 true WO2015023553A3 (en) 2015-04-23

Family

ID=52468603

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2014/050463 Ceased WO2015023551A1 (en) 2013-08-13 2014-08-10 Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
PCT/US2014/050465 Ceased WO2015023553A2 (en) 2013-08-13 2014-08-10 Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur- containing, amino acid-specific small molecules
PCT/US2014/050464 Ceased WO2015023552A1 (en) 2013-08-13 2014-08-10 Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2014/050463 Ceased WO2015023551A1 (en) 2013-08-13 2014-08-10 Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2014/050464 Ceased WO2015023552A1 (en) 2013-08-13 2014-08-10 Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types

Country Status (2)

Country Link
EP (1) EP3033150A4 (en)
WO (3) WO2015023551A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11242530B2 (en) 2016-12-08 2022-02-08 Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd siRNA knocking down human PD-1 and recombinant expression CAR-T vector and their construction methods and applications
CN108770360B (en) * 2016-01-27 2022-06-14 弗劳恩霍夫应用研究促进协会 Means and methods for staging, typing and treating cancerous diseases

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2773777B1 (en) 2011-10-31 2020-05-13 University of Utah Research Foundation Genetic alterations in glioblastoma
WO2016168525A1 (en) * 2015-04-14 2016-10-20 University Of Utah Research Foundation Genetic alterations in ovarian cancer
CN105198790B (en) * 2015-04-20 2018-02-16 范国煌 Promote the tetracyclic compound of double negative t cells in-vitro multiplication
US20200377955A1 (en) * 2017-06-20 2020-12-03 Liquid Genomics, Inc. USE OF CELL-FREE CIRCULATING RNA (cfRNA) EXPRESSION OF PD-L1 AND ERCC1 IN PLASMA TO MONITOR RESPONSE TO THERAPY IN NSCLC
CN113461952B (en) * 2021-06-30 2022-07-01 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Active oxygen-responsive self-degrading polymer and preparation method and application thereof
CN118103949A (en) * 2021-09-15 2024-05-28 英飞凌科技有限责任公司 How to integrate SONOS into HKMG streaming

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070404A1 (en) * 2010-09-16 2012-03-22 Bionumerik Pharmaceuticals, Inc. Increasing cancer patient survival time by administration of dithio-containing compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550430A (en) * 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
EP1968607B1 (en) * 2005-12-02 2014-01-15 Nabil Habib Lab Treatment of cancer and other diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070404A1 (en) * 2010-09-16 2012-03-22 Bionumerik Pharmaceuticals, Inc. Increasing cancer patient survival time by administration of dithio-containing compounds

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GAZDAR ET AL.: "Activating and resistance mutations of EGFR in non-small- cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.", ONCOGENE, August 2009 (2009-08-01), pages S24 - S31, XP055018935, DOI: doi:10.1038/onc.2009.198 *
HORNE ET AL.: "Why imatinib remains an exception of cancer research .", J CELL PHYSIOL, vol. 228, no. 4, April 2013 (2013-04-01), pages 665 - 670 *
KRAPFENBAUER ET AL.: "Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders.", BRAIN RES, vol. 967, no. 1-2, 28 March 2003 (2003-03-28), pages 152 - 160 *
PARKER ET AL.: "BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro.", MOL CANCER THER, vol. 9, no. 9, September 2010 (2010-09-01), pages 2558 - 2567 *
POLLAK ET AL.: "Cytoskeleton derangement in brain of patients with Down syndrome, Alzheimer's disease and Pick's disease.", J NEURAL TRANSM, vol. 67, 2003, pages 149 - 158, XP009156986, DOI: doi:10.1007/978-3-7091-6721-2_13 *
SHAW ET AL.: "Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.", N ENGL J MED, vol. 368, no. 25, 1 June 2013 (2013-06-01), pages 2385 - 2894 *
TSAO ET AL.: "Erlotinib in lung cancer - molecular and clinical predictors of outcome.", N ENGL J MED, vol. 353, no. 2, 14 July 2005 (2005-07-14), pages 133 - 144, XP007905868, DOI: doi:10.1056/NEJMoa050736 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108770360B (en) * 2016-01-27 2022-06-14 弗劳恩霍夫应用研究促进协会 Means and methods for staging, typing and treating cancerous diseases
US11242530B2 (en) 2016-12-08 2022-02-08 Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd siRNA knocking down human PD-1 and recombinant expression CAR-T vector and their construction methods and applications

Also Published As

Publication number Publication date
EP3033150A1 (en) 2016-06-22
WO2015023552A1 (en) 2015-02-19
WO2015023553A2 (en) 2015-02-19
WO2015023551A1 (en) 2015-02-19
EP3033150A4 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
WO2015023553A3 (en) Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
CR9949A (en) 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITORS (FLAP)
UY31067A1 (en) 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITORS (FLAP)
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
EA202091999A3 (en) APPLICATION OF DPP IV INHIBITORS
BR112015028278A2 (en) process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and erythrocytes thus obtained
BR112018008805A8 (en) dual-function proteins and pharmaceutical composition comprising the same
BR112012018500A2 (en) some quinurenine-3-monooxygenase inhibitors, pharmaceutical compositions and methods of use thereof
BR112014032699A2 (en) Pediatric metabolic syndrome treatment methods
EA200901166A1 (en) CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS
EA201790267A1 (en) NEW KINAZ MODULATORS
HK1209633A1 (en) Compositions and methods for treating diabetes
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
EA201300669A1 (en) SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
BR112018008676A2 (en) long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
EP4553065A3 (en) Novel compounds for treating mitochondrial disease
UA107550C2 (en) ESTRA-1,3,5 (10), 16-TETRAEIN-3-CARBOXAMAMID DERIVATIVES, THE METHODS OF THEIR PREPARATION, THE PHARMACEUTICAL PREPARATIONS THEREOF, AND THEIR USE
WO2015187295A3 (en) Methods of lowering serum cholesterol
EA201401231A1 (en) PHARMACEUTICAL COMBINATIONS INTENDED FOR THE TREATMENT OF METABOLIC DISORDERS
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
BR112016000658A2 (en) high activity pancreatin, a process for the preparation of aa pancreatin having specific lipase activity of at least approximately 120 usp iu / mg and method of treating a patient subject to a pathological condition associated with pandreatic enzyme insufficiency
BRPI0615690B8 (en) heterocyclic hydroxamate compounds, their uses and pharmaceutical composition
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
WO2018005794A3 (en) Novel non-systemic tgr5 agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14836589

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14894047

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01/07/2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14836589

Country of ref document: EP

Kind code of ref document: A2